Evidence-based PET in cardiovascular infectious diseases: an umbrella review.

Q J Nucl Med Mol ImagingJun 16, 2026 (epub)
Clinical ResearchCardiologyInfectious Diseases

Domenico Albano, Slavko Tasevski, Stefano Panareo

✦ AI-curated · Sources linked

In 30 seconds

[18F]FDG PET/CT's diagnostic performance for cardiovascular infections was evaluated in this systematic review of systematic reviews. The findings indicate that this imaging modality has good accuracy for detecting prosthetic valve endocarditis, cardiac device infections, and vascular graft infections, but is less effective for native valve endocarditis.

Key findings

  • [18F]FDG PET/CT shows good diagnostic accuracy for prosthetic valve endocarditis.
  • The imaging technique is effective for detecting infections in cardiac implantable electronic devices and left ventricular assist devices.
  • Accuracy is suboptimal for patients with native valve endocarditis.

Why it matters

Understanding the diagnostic capabilities of [18F]FDG PET/CT can aid clinicians in accurately identifying cardiovascular infections, which is crucial for timely and appropriate management.

Source

PubMed · PMID 42299130

Published in Q J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.